News Updates

More Articles Back to Article

Roche, Jnana sign 2nd deal worth up to $2B

Jnana Therapeutics has signed a second research and licensing deal with Roche worth up to $2 billion for small molecule discovery and development, with $50 million to be paid to Jnana as an upfront payment, and the company raised an additional $107 million through a Series C funding round. The collaboration will utilize Jnana's RAPID chemoproteomics platform for the discovery of novel small molecule drugs that can treat cancer tumors and neurological diseases. BioSpace (San Francisco) (11/15)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!